Gastric Cancer Incidence Increasing in Younger Population in Latin America

Article

A new study found an upward trend over the last 12 years of cases of gastrointestinal cancer in young patients in Latin America.

The incidence of gastric cancer in younger people increased substantially over a 12-year period in Latin America, according to a new study. The increase was seen primarily in young women, who often presented with more advanced disease.

“Gastric cancer has been considered a disease of the older population worldwide,” wrote study authors led by Germán Calderillo-Ruiz, MD, of the National Cancer Institute in Tlalpan, Mexico. He presented results of the new retrospective, observational study at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2019, held July 3-6 in Barcelona, Spain.

The study included a total of 2,022 patients with gastric adenocarcinoma, treated between 2004 and 2016 at INCAN Mexico. Of that total, 290 patients (14%) were 40 years of age or under; of those younger patients, 54% were women. The mean age of both women and men among the younger patients was 34.6 years. The study found a 120% increase over the 12-year study period of patients aged 40 years or younger.

Most of the primary tumors in this younger cohort were gastric (93%), followed by the esophagogastric junction (7%). Most patients presented with stage IV disease (76%), followed by 16% with locally advanced disease and 8% with stage I–III gastric cancer.

Compared with men, women presented with higher rates of poor prognostic factors. A total of 68% of women had diffuse-type histology compared with 32% of men (P = 0.127); more women had ring-seal cells (76% vs 69%; P = 0.049), poorly differentiated gastric cancer (89% vs 84%; P = 0.014), and were more likely to present with stage IV disease (59% vs 41%; P = 0.011).

The median overall survival (OS) for the women in the study was 7 months, compared with 8 months for men, for a hazard ratio of 1.29 (95% CI, 1.05–1.65; P = 0.030). The median OS was longer for patients with esophagogastric junction tumors than with gastric tumors.

A multivariate analysis found that gender was an independent predictor of overall survival, with an HR of 1.29 (95% CI, 1.01–1.65; P = 0.038). Primary tumor site and clinical stage at presentation were also independent predictors of survival, while histology was not significantly associated.

“The lack of financial resources may impact on women’s behaviour of delaying pursuit of medical care when gastric symptoms appear,” Calderillo-Ruiz said. “We hope this research will encourage clinicians and patients to be more aware of the risk of gastric cancer in younger people and, in particular, to encourage women with gastric symptoms to seek medical help sooner.”

Rodrigo Dienstmann, MD, of Vall d’Hebron Institute of Oncology in Barcelona, who commented on the study for ESMO, noted the combination of genetic and environmental factors that go into the development of gastric cancer.

“We cannot change the genetic factors, but we can act on the unhealthy diet, obesity, and untreated Helicobacter pylori infection which increase the risk of gastric cancer,” he said. “Helicobacter infection can cause chronic inflammation and lesions that are precursors to gastric cancer but, once diagnosed, can be cured with a combination of antibiotics and drugs to reduce stomach acid.”

He stressed that younger people who regularly experience heartburn or other gastric symptoms should consult a physician, while clinicians should be aware that gastric cancer is not uncommon among younger individuals.

Related Videos
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content